1. Whether the Intermediary properly disallowed the Provider's request for an adjustment to the TEFRA rate-of-increase ceiling
to account for the cost of new drugs that were not approved in the 1983 base year.; 2. Whether the Intermediary properly calculated
the Provider's 1996 reasonable cost that were included in the denominator of the fraction used to determine the payment-to-cost
ratio for purposes of the Outpatient Prospective Payment System (OPPS) hold harmless payment.
University of Texas M.D. Anderson Cancer Center, Houston TX